We therefore constructed a double mutant Tau V337M; cca-1(ad1650) strain to determine if ethosuximide’s therapeutic action in the frontotemporal dementia model was mediated via inhibition of CCA-1. The gene discussed is MAPT; the disease is frontotemporal dementia.